Clinical Trial Update: Extension From Weekly to Once Every Other Week Darbepoetin Alfa Administration in Subjects With Chronic Kidney Disease Receiving Dialysis [Phase 3]

View source ↗

Summary

Phase 3 trial update showing extension of darbepoetin alfa dosing from weekly to every other week in subjects with chronic kidney disease on dialysis.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease

Drugs mentioned

• darbepoetin alfa (darbepoetin alfa)

Snippet

Sponsor: Amgen | Conditions: Chronic Kidney Disease | Phase 3 | Status: COMPLETED